[Pentoxifylline: a cheap substitute for anti-TNFalpha agents?]

Area of Science:

• Pharmacology
• Immunology

Context:

• Pentoxifylline (PTX) is a phosphodiesterase inhibitor with demonstrated in vitro anti-tumor necrosis factor-alpha (anti-TNFalpha) properties.
• Inflammatory rheumatic and non-rheumatic diseases are characterized by inflammatory processes that can be targeted by anti-TNFalpha agents.

Purpose:

• To selectively review clinical trials investigating the use of Pentoxifylline (PTX) in patients with inflammatory rheumatic and non-rheumatic diseases.
• To evaluate the preliminary efficacy and safety of PTX in various inflammatory conditions based on existing clinical data.

Summary:

• A review of clinical trials indicated that Pentoxifylline (PTX) yielded significant preliminary results in systemic lupus erythematosus, Behçet's disease, and sarcoidosis.
• PTX demonstrated a marked reduction in proteinuria across several types of glomerulonephritis, including lupus nephritis, membranous nephropathy, and diabetic nephropathy.
• Most reviewed trials were uncontrolled and involved small patient cohorts, limiting definitive conclusions.

Impact:

• The findings suggest potential therapeutic benefits of Pentoxifylline (PTX) in specific inflammatory diseases, particularly those involving TNFalpha.
• Further rigorous, randomized, and controlled clinical trials are essential to confirm the efficacy of PTX in improving patient outcomes for these conditions.
• Currently, PTX is not recommended for the treatment of inflammatory diseases due to insufficient evidence from high-quality studies.